clinical trial · NCT04384484
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics S.A.·phase3·active not recruiting·n = 440
Relapsed Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaLoncastuximab TesirineRituximabGemcitabineOxaliplatin
brief summary
The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.
started
Sep 16, 2020
primary completion
Mar 31, 2026
completion
Jun 30, 2028
last updated
Mar 24, 2026
official title
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol